Proposal Final - May

THE RELATIONSHIP BETWEEN DEPRESSION AND SUBJECTIVE QUALITY OF LIFE IN NIGERIAN OUTPATIENTS WITH SCHIZOPHRENIA OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITALS COMPLEX, ILE-IFE PRINCIPAL INVESTIGATOR: DR. AKINSULORE ADESANMI

DEPARTMENT OF MENTAL HEALTH OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITALS COMPLEX

PROPOSAL SUBMITTED IN PARTIAL FULFILLMENT OF THE PART II FELLOWSHIP EXAMINATION OF THE WEST AFRICAN COLLEGE OF PHYSICIANS FACULTY OF PSYCHIATRY

SUPERVISORS: PROF R O A MAKANJUOLA DR F O FATOYE

1

CERTIFICATE OF SUPERVISION

This is to certify that I am supervising the project titled “The relationship between depression and subjective quality of life in Nigerian outpatients with Schizophrenia” by Dr. Adesanmi Akinsulore as a requirement for his part II West African College of Physicians, Faculty of psychiatry qualification.

Signature ………………………………………

Date ……………………….

Prof. R.O.A Makanjuola, FWACP, FMCPsych

Head of Department

Signature ……………………………………… Dr D.I Ukpong, FMCPsych

2

Date ……………………….

TABLE OF CONTENT 1.

NAME OF CANDIDATE

6

2.

FACULTY OF CANDIDATE

6

3.

TRAINING INSTITUTION

6

4.

ADDRESS OF TRAINING INSTITUTION

6

5.

NAME OF SUPERVISOR

6

6.

ADDRESS OF SUPERVISOR

6

7.

NAME OF SECONDARY SUPERVISOR

6

8.

ADDRESS OF SECONDARY SUPERVISOR

6

9.

MONTH AND YEAR PART I PASSED

6

10.

PROPOSED EXAMINATION DATE

6

11.

PROPOSED TITLE OF PROJECT

6

12.

AIMS AND OBJECTIVES OF THE STUDY

7

13.

PROPOSED METHODOLOGY

9

13.1

SUBJECTS

9

13.2

STUDY DESIGN

9

13.3

SAMPLE SIZE

10

13.4

PROCEDURE

10

13.5

MEASURES

10

13.6 STATISTICAL ANALYSIS 14

14

LITERATURE REVIEW

15

14.1

PREAMBLE

15

14.2

DEFINITION

16

3

14.3 METHODOLOGICAL ISSUES

16

14.4 DEPRESSION IN SCHIZOPHRENIA

18

14.5 DIFFERENTIAL DIAGNOSIS OF DEPRESSION IN THE COURSE OF SCHIZOPHRENIA

19

14.51 MEDICAL OR ORGANIC FACTORS

20

14.52 NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

20

14.53 NEUROLEPTIC INDUCED DYSPHORIA

21

14.54 NEUROLEPTIC INDUCED AKINESIA

21

14.55 NEUROLEPTIC INDUCED AKATHISIA

22

14.56 REACTIONS TO DISAPPOINTMENT OR STRESS

22

14.57 POST PSYCHOTIC DEPRESSION

22

14.58 SCHIZOAFFECTIVE DEPRESSION

23

14.6

QUALITY OF LIFE IN SCHIZOPHRENIA

23

14.7

FACTORS AFFECTING QUALITY OF LIFE

26

15.

RELEVANCE OF THE PROPOSED PROJECT TO THE PRACTICE OF PSYCHIATRY

28

16.

APPLICATION SUPPORT

29

17.

FOR OFFICIAL USE

30

18.

REFERENCES

31

19.

APPENDIX

43

19.1

SOCIO-DEMOGRAPHIC QUESTIONNAIRE

19.2

ILLNESS RELATED DETAILS

43

19.3

MEDICATION RELATED DETAILS

44

4

43

19.31

SIDE EFFECT CHECKLIST

44

19.32

SIMPSON ANGUS SCALE

44

19.4

INSIGHT INTO ILLNESS

44

19.5

MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (MINI)

19.6

45

POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS)

19.7

48

ZUNG’S SELF-RATING DEPRESSION SCALE

50

19.8 WORLD HEALTH ORGANIZATION QUALITY OF LIFE SCALE – BRIEF VERSION (WHOQOL-BREF) 19.9

INFORMED CONSENT FORM

51 55

5

WEST AFRICAN COLLEGE OF PHYSICIANS RESEARCH PROPOSAL AND TITLE REGISTRATION ASSESSMENTS FORM OF PART II CANDIDATES 1.

NAME OF CANDIDATE:

AKINSULORE, Adesanmi

2.

FACULTY OF CANDIDATE:

Psychiatry

3.

TRAINING INSTITUTION:

Obafemi Awolowo University Teaching

Hospital Complex (OAUTHC), Ile-Ife. 4.

ADDRESS OF TRAINING INSTITUTION:

Obafemi Awolowo University

Teaching Hospitals Complex (OAUTHC), Ile-Ife, Osun State, Nigeria. 5.

NAME OF SUPERVISOR:

Prof. R.O.A. Makanjuola

6.

ADDRESS OF SUPERVISOR:

Department of Mental Health Obafemi

Awolowo University, Ile-Ife, Osun State, Nigeria. 7.

NAME OF SECONDARY SUPERVISOR:

Dr. F.O. Fatoye

8.

ADDRESS OF SECONDARY SUPERVISOR:

Department of Mental

Health, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 9.

MONTH AND YEAR PART I PASSED: OCTOBER 2008

10.

PROPOSED EXAMINATION DATE:

OCTOBER 2010

11.

PROPOSED TITLE OF PROJECT:

The Relationship between

Depression and Subjective Quality of Life in Nigerian Outpatients with Schizophrenia.

6

12.

AIMS AND OBJECTIVES OF THE STUDY: Schizophrenic disorders afflict approximately 1% of the population during their

lifetime. These disorders impose severe hardships on patients and their families and challenge society in the development of public policies that both preserve the public welfare and afford patients a decent quality of life (QOL) (Lehman, 1996). QOL refers to the health-related aspect of personal well-being or, when expanded to encompass the psychosocial aspects, a subjective perception of health (Bohmer and Ravenssieberer, 2005). Psychiatric research employs QOL as a discriminating, predictive and evaluating indicator of well-being (Pukrop, 2003). Several variables have been studied in relation to subjective QOL. Depression has been found to be inversely related to subjective QOL among outpatients with serious mental illness (Fitzgerald et al, 2001; Huppert et al, 2001; Reine et al, 2003; Tomotake et al, 2006; Aki et al, 2008; Yamauchi et al, 2008). Depressive symptoms play an important role in schizophrenia as these contribute to a further worsening of any already existing deficit state, i.e., negative symptoms (Murali & Kumar, 2008). Therefore, it becomes important and essential to clearly delineate depressive symptoms from deficit states (Negative Symptoms) and manage them appropriately in order to improve the clinical outcome. A search of the literature revealed a dearth of published research on the relationship of depression on the subjective quality of life of patients presenting with schizophrenia in the West African environment. The overall aim of this study is to assess the relationship between depression and subjective quality of life in outpatients with schizophrenia.

7

The specific objectives of this study are as follows: 1.

To examine the perception of patients with schizophrenia on their overall QOL as well as their level of satisfaction with the physical, psychological, social and environmental domains of their living experience.

2.

To

identify

and

compare

depressed

and

non-depressed

schizophrenic patients in terms of subjective QOL and psychopathological symptoms. 3.

To evaluate the socio-demographic and clinical variables that may be associated with the subjective QOL in patients with schizophrenia.

4.

To compare the relationship between subjective quality of life and positive and negative symptoms of schizophrenia

Hypothesis The hypotheses of this study are as follows: 1.

There will be no significant difference in the subjective quality of life of depressed and non-depressed Schizophrenic outpatients.

2.

There will be no significant association between sociodemographic and clinical characteristics of depressed and nondepressed Schizophrenic outpatients

3.

There will be no significant association between the subjective quality of life and positive and negative symptoms of schizophrenia

8

13. 13.1

PROPOSED METHODOLOGY SUBJECTS: The subjects will be recruited from the outpatients’ psychiatric

clinic of Wesley Guild Hospital, Ilesa, a unit of the Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Osun State. They will be consecutively recruited over a period of six months. The inclusion criteria into the study will be: 1.

Adults aged 18 years and above.

2.

Having been diagnosed as having schizophrenia using ICD – 10 criteria which is the diagnostic nosology used by the department. All patients presenting in the unit are interviewed based on the ICD – 10 diagnostic criteria and the final diagnosis recorded in a departmentally structured diagnosis plan sheet available for research purposes and also submitted for input into the hospital’s computerized diagnostic register. The diagnosis of schizophrenia will be confirmed by the researcher using the Mini International Neuropsychiatric Interview (MINI) English Version 5.0.0 (Sheehan et al 1998).

3.

The patients should have been diagnosed and receiving treatment for at least 1 year before inclusion in the study.

4.

The last hospital admission must be at least 6 months or more before the date of assessment and

9

5.

There must be no evidence of organic disease or mental retardation and significant physical illness such as hypertension.

13.2

STUDY DESIGN:

A cross-sectional descriptive survey.

13.3

SAMPLE SIZE: The required sample size for the study group will be calculated

using the formula according to Fleiss (1981). N

=

C

[2

( Pc) + Qc ] d2

+

2 + 2 d

Where C is a constant that depends on the values for alpha (significance level) and beta (power) with alpha set at 0.05 and beta at 90% then C = 10.51 Pc :

the estimate of the proportion of outcome set at 50% (0.5)

Qc = 1 - Pc d =

differences in the outcome ( 1 - 0.5) = 0.5

N =

10.51 [2 (0.5) + 0.5] 0.5 X 0.5

+

2 0.5

+ 2

N = 69.06 Adding 10% attrition rate = 6.906 + 69.06 = 75.97 A sample size of 100 will be chosen in order to increase the statistical power. 13.4

PROCEDURE Approval of the research protocol by the Ethics and Research Committee of

Obafemi Awolowo University Teaching Hospitals Complex will be obtained and written informed consent will be taken from the subjects after the aims of the study have been explained to them. 13.5

MEASURES 10

1.

The Clinical Interview: The diagnosis of schizophrenia will be ascertained with the Mini International Neuropsychiatric Interview (MINI), English Version 5.0.0 (Sheehan et al 1998). The MINI was designed as a brief structured interview for the major AXIS I psychiatric diagnoses in the DSM IV and ICD-10. Validation and reliability studies done comparing the MINI to other similar structured interviews such as the Structured Clinical Interview for the DSM-IV Patient version (SCID – P, First et al, 1994) and the Composite International Diagnostic Interview (CIDI; Smeets and Dingemans, 1993) have shown high validity and reliability scores. The MINI has a current (for present symptoms) and a lifetime version (for retrospective diagnosis). The lifetime diagnosis version will be used in this study. The instrument has been used in Nigeria (Adewuya et al, 2008)

2.

A semi–structured questionnaire inquiring about socio-demographic and illness related variables of the subjects. The illness-related variables will also be obtained with the use of specific instruments and a review of the patient’s case file. The information obtained will include:

2.1

Age, sex, marital status, religion, ethnicity, highest level of formal education, occupation, current employment status.

2.2

Earnings/income per month, amount spent on treatment per month, residential type, housing condition, mode of transport, domestic situation, leisure activities, relationship with same and opposite gender and level of social support from family members, friends and others..

11

2.3

Duration of the illness, age of onset of active symptoms of schizophrenia, past history of hospital admissions, number of hospital admissions

2.4 Psychopathological symptoms: These will be assessed with the Positive and Negative Syndrome Scale (PANSS; Kay et al, 1987) which includes a structured interview to assess patients on 30 items covering positive, negative and general symptoms. For each item, ratings are made on a 1 – 7 scale of symptom severity. The scale has been used in Nigeria (Mccreadie and Ohaeri, 1994; Lawal et al, 2003). 2.5

Depression: This will be assessed using the Zung’s self-rating depression scale (SDS; Zung WWK, 1965) which is a 20- item self administered questionnaire with 4 fold likert’s scale (Never, occasionally, sometimes, mostly) in answering each question. The sum of scores (raw scores) for each respondent will be converted to a 100 point scale (SDS Index Score) with a score of less than 50 points classified as normal, 50-59 points classified as mild depression, 60-69 points classified as moderate depression and 70 and above points classified as severe depression. The instrument and its back translated Yoruba version has been used in Nigeria (Jegede, 1979; Fatoye et al, 2004; Mosaku et al, 2008).

2.6

Level of Functioning: This will be assessed with the Global Assessment of Functioning scale (GAF; APA, 1994). This is an observer-rated single rating on a 100 point scale, where 100 indicates not only the absence of pathology but also positive mental health.

2.7

Insight into Illness: A semi structured questionnaire based on the Present State Examination (Wing et al., 1974) will be used to enquire about patients’ awareness of their own mental state.

12

3.

Medication Related Variables: These will be assessed with the use of a questionnaire and a review of the patient’s case file. It will include the following:

3.1

Type and dose of current antipsychotic and anticholinergic medications.

3.2

Side effects of antipsychotic medication – These will be assessed with the aid of a clinician-rated structured check list detailing common side-effect symptoms. Each symptom is scored on as present or absent. This check list has been standardized and used in the unit (Adewuya, 2007).

4.

The Subjective Quality of Life: This will be measured using the World Health Organization Quality of Life Scale – Brief version (WHO QOL – BREF) which is a 26-item self-administered generic questionnaire. It is a short version of the WHO QOL – 100 scale (the WHO QOL Group, 1998). The WHO QOL – BREF is an international quality of life instrument which produces a profile with four domain scores: physical health (7 items), psychological health (6 items), social relationships (3 items), environmental domain (8 items) as well as two separately scored items about the individuals’ perception of their quality of life (QI) and health (Q2). Each item is scored in a Likert format from 1 to 5. The WHO QOL – BREF has been validated across a wide variety of cultures, including Nigeria. (Olusina and Ohaeri, 2003). Either the English version or the back-translated Yoruba version of the instrument (Sokoya, 1999; Adeponle, 2003) will be administered on the patients. Literate subjects will be given the instrument to fill and for the non-literate subjects the researcher will read the questions out to the patients and tick the answers.

13

13.6

STATISTICAL ANALYSIS The Statistical Package for the Social Sciences 11 (SPSS 11) program will be used for statistical analysis. The domain scores of the WHO QOL – BREF will be calculated according to the instructors’ manual. Descriptive statistics will be used for all variables while inferential statistics such as chi-square test, independent ttest, and Pearson’s correlations will be used to identify the relationships between QOL and the variables assessed.

14

14 14.1

LITERATURE REVIEW Preamble In recent years, great attention has been given to quality of life (QOL) in

schizophrenia and factors related to patients’ QOL (Yamauchi et al, 2008). Among the various clinical factors related to levels of QOL, depression has been suggested to be the most important determinant for subjective QOL (Fitzgerald et al, 2001; Huppert et al, 2001; Reine et al, 2003; Tomotake et al, 2006; Aki et al, 2008; Yamauchi et al, 2008). From the literature, the rate of depression among schizophrenic patients ranges from 6% - 75% in the course of psychosis in general (Gorna et al, 2007). In first psychotic episodes and psychotic relapses the prevalence of depression varies from 65 – 80% and in the psychosis free intervals from 4-20% (Hafner et al, 2005). It has also been reported that a large proportion (30 – 40%) of schizophrenic patients present with full depressive syndromes and that this was associated with poor overall outcome, characterized by significant work impairment, lower activity, dissatisfaction, less employment, suicidal tendencies, more rehospitalization and more psychosis than the patients with primary major depression (Sands and Harrow, 1999; Wassink et al, 1999; Gorna et al, 2007). The variations in the prevalence rates may be due to methodological and sampling differences as well as differences in the definition of both schizophrenia and depression that were employed in the various studies.

15

14.2

Definition QOL is a highly complex concept and difficult to define. The World Health Organization Quality of life Group (WHO QOL Group) defined QOL as the “individuals’ perception of their position in life in the context of the culture and value system in which they live and in relation to their goals, expectations, standards and concerns” (Harper and Power, 1998). It is a broad-ranging concept, affected in a complex way by the person’s physical health, psychological state, level of independence, social relationships and their relationship to salient features of their environment. According to the WHO (1944) health is a “state of complete physical, mental and social well being and not merely the absence of disease or infirmity”. Only partially in keeping with this definition, psychiatric interventions have focused mostly on the treatment of symptoms. Expanding the outcome measures in psychiatry, for example by using subjective quality of life (SQOL), is thus warranted. In accordance with the definition of health by the WHO, SQOL covers physical, emotional, mental, social and behavioural components of well-being and functions as perceived by each individual.

14.3

Methodological Issues The methodological requirements for a useful quality of life instrument are that it be reliable, valid, sensitive to change and relatively brief (assuming that it will be part of a larger battery of assessments). The ideal instrument is one that is suitable for different patient groups, yet specific enough to be sensitive to the effects of

16

particular treatments. At this time, no single instrument has been tested across diverse patient samples. QOL has been measured from two different viewpoints. One is subjective QOL, rated by patients themselves, and the other is objective QOL, rated by observers. Patients with schizophrenia were thought to be unable to assess their QOL themselves because of their cognitive deficit function (Atkinson et al, 1996; Yamauchi et al, 2008) and objective QOL has been frequently used in many studies. However, now there is general agreement that symptomatically stabilized patients are able to evaluate their QOL themselves (Voruganti et al, 1998). More importantly, Hunt (1988) asserts that quality of life ‘refers essentially to a subjective assessment of the situation by the patient - the only person with sufficient relevant knowledge to make that assessment’. While a host of studies have examined quality of life or subjective well being using schizophrenia – specific scales (Heinrichs S et al, 1984; Naber et al, 2001; Wilkinson et al, 2000) these scales have not been validated among West African schizophrenic patients. Another methodological issue is that evaluation of depression in schizophrenia is subject to several difficulties. The contamination of depressive symptoms by negative or extra pyramidal symptoms constitutes a frequent bias. The Zung’s self-Rating depression scale is a measure which has been found useful in the assessment of depression among schizophrenic patients (Kaneda, 1999). Also, the instrument has been used by several researchers in Nigeria (Jegede, 1979; Fatoye et al, 2004; Mosaku et al, 2008).

17

14.4

Depression in Schizophrenia A number of systematic studies of persons suffering from schizophrenia have

observed that there is often a significant co-occurrence of depression (Siris, 1995). The term “depression” in schizophrenia could be considered from three different viewpoints; whether it is the affect of depression, the symptom of depression or the syndrome of depression (Siris, 2000). This has been a source of confusion and has confounded the schizophrenia literature. Depression as an affect reflects an individual’s momentary mood state on the subjective experience spectrum from happiness to sadness as he or she interacts with his or her internal and external environment. It is not, in itself, pathological as long as it is situationally appropriate. Depression as a symptom is a sad mood state that causes a person distress. It is an unwanted painful feeling and can be a source of complaint. However, it is not necessarily enduring or accompanied by other features that are required for the diagnosis of the syndrome of depression (Siris, 2000). The depression syndrome is a complex feature that typically involves the symptom of depression but also includes cognitive and vegetative features such as pessimism, guilt, impaired concentration, lack of confidence, loss of interest or pleasure and disturbance of sleep, appetite and energy level. Differences in the definition of depression may account for some of the discrepancies in the reported occurrence rates and treatment responses of depression in schizophrenia (Siris, 2000). Depression in patients with schizophrenia has been shown to be associated with a family history of depression, early parental loss, and higher doses of depot neuroleptics; no significant gender difference has been found (Subotnik et al, 1997; Addington et al,

18

1996; King et al, 1995). The association of depressive symptoms with attentional difficulties suggests frontal lobe dysfunction and volume changes in temporal lobes (Kholer et al, 1988; Kholer et al, 1998) and some neurobiological similarities between schizophrenia and depressive illness. Vaillant (1964) reported that the presence of depression confers a favourable prognosis in schizophrenia. However, other studies have suggested that depression is a precursor of relapse (Herz and Melville, 1980; Becker 1988), may increase the risk for rehospitalization (Herz and Melville, 1980) and is likely to be associated with demoralization, hopelessness (Drake and Cotton, 1986) and impaired psychosocial skills (Glazer et al, 1981). Most importantly, the presence of depression may put the patient with schizophrenia at risk for suicidal thoughts and, ultimately, completion of a suicide attempt (Addington and Addington, 1992). Therefore,

accurate

identification

of

depression

among

patients

with

schizophrenia is vital. 14.5

Differential Diagnosis of Depression in the Course of Schizophrenia While considering the possibility of depression in schizophrenia, a number of

differentials have to be kept in mind. These include medical or organic causes, negative symptoms of schizophrenia, neuroleptic induced negative symptoms and schizoaffective disorder (Bartels and Drake, 1988; Kirkpatrick and Fischer, 2006). Depressive symptoms may also be a psychological reaction to the illness or it might be one of the core features of schizophrenia (Mulholland and Cooper, 2000).

19

14.51 Medical or Organic Factors A number of medical or organic factors can present as depression in patients with schizophrenia (Bartels and Drake, 1988). These include cardiovascular disorders, pulmonary infections, autoimmune diseases, anaemia, cancer, metabolic, neurological and endocrine disorders. Various pharmaceuticals used in medical treatment such as B – Blockers, other antihypertensive agents, sedative hypnotics, antineoplastics and sulphonamides can cause depression as a side effect. Depression can also accompany the discontinuation of other prescribed drugs such as corticosteroids and psycho-stimulants. Used or abused substances such as alcohol, cannabis, cocaine or narcotics can contribute to depression either on the basis of acute use, chronic use or discontinuation. It is also important to note that the discontinuation of nicotine and caffeine can lead to withdrawal states that potentially mimic depression (Dalack et al, 1998; Griffitus and Mumford, 1995). 14.52 Negative Symptoms of Schizophrenia The negative symptoms syndrome of schizophrenia overlaps with the syndrome of depression in a number of important respects (Andreason and Olsen, 1982; Carpenter et al, 1985; Siris et al, 1988; Bermanzohn and Siris, 1992). Diminished interest, pleasure, energy, or motivation along with psychomotor retardation and impaired ability to concentrate are relevant overlapping features. However, certain other symptoms may be more distinguishing (Lindenmayer et al, 1991; Kuck et al, 1992; Kibel et al, 1993). Blunted affect, for example, suggests negative symptoms whereas distinct blue mood or cognitive features, such as guilt or suicidal thoughts suggest depression. However, these

20

two states can sometimes be difficult to differentiate if patients lack the interpersonal communication skills to articulate their internal subjective states well. 14.53 Neuroleptic Induced Dysphoria Dopamine synapses are involved in brain pathways mediating “reward” (Wise, 1982; Harrow et al, 1994). Therefore, dopamine blockade by a neuroleptic drug could theoretically lead to anhedonia and perhaps, depression. The relationship between neuroleptic use and depression remain controversial. A number of older anecdotal reports have suggested a link between neuroleptic use and depression (De Alarcon and Carney, 1969; Floru et al, 1975; Johnson, 1981; Galdi, 1983) and one study found more anhedonia and depression in maintenance phase schizophrenic patients who were taking neuroleptics than in others who were not (Harrow et al, 1994). Another study found a positive relationship between haloperidol plasma levels and depressive symptoms in the context of a positive association between extra pyramidal symptoms and depressive symptoms (Krakowsi et al, 1997). Also, impairments of quality of life related to neuroleptic induced dysphoria have been reported. (Browne et al, 1998). Nevertheless, the majority of controlled studies tend to refute the proposition that neuroleptic medication is regularly responsible for the development of depressive state in schizophrenia (Knights and Hirsch, 1981; Siris, 1991). 14.54 Neuroleptic Induced Akinesia Akinesia is usually defined as “large muscle stiffness”. However Rifkin et al, (1975; 1978) and Vanputten & May (1978) were able to describe a more subtle but equally debilitating extrapyramidal side effect of neuroleptic treatment involving impaired ability to initiate and sustain motor behaviour. Patients with this form of

21

akinesia may or may not have the classical parkinsonian features of decreased accessory motor movements. Patients themselves may attribute this effect to “Laziness”, experiencing guilt or shame. Blue mood can also accompany this condition, possibly as a primary issue (Van Putten & May, 1978), making it virtually indistinguishable clinically from depression.

14.55 Neuroleptic Induced Akathisia Akathisia is another extrapyramidal side effect of neuroleptic treatment that, in subtle presentation, can easily be confounded with depression (Van Putten, 1975). Patients experience this state as substantially dysphoric (Van Putten, 1975; Halstead et al, 1994). Also akathisia has been associated with both suicidal ideation and suicidal behaviour (Shear et al, 1983; Drake and Ehrlich, 1985). 14.56 Reactions to Disappointment or Stress Reactions to disappointments, a sense of loss or powerlessness over psychotic symptoms or psychological deficits can present as or follows closely after a stressful event or exacerbation of schizophrenia (Birch wood et al, 1993; Liddle et al, 1993; Lysaker et al, 1995) 14.57 Post Psychotic Depression This term was earlier used to describe a dysphoric state that immediately followed a psychotic episode (Mcglashan and Carpenter, 1976). DSM-IV now suggests that the term “post psychotic depression” be used to describe depression that occurs at any time after a psychotic episode in schizophrenia

22

14.58 Schizoaffective Depression The term schizoaffective disorder was first used in the early 1930s to describe patients showing an overlap of features of schizophrenia and affective illness (Kasanin, 1933). In DSM IV, schizoaffective disorder refers to patients in whom a full affective syndrome coincides with the florid psychotic syndrome but who also have substantial periods of psychosis in the absence of an affective syndrome. In ICD 10, schizoaffective disorder refers to episodic disorder in which both affective and schizophrenic symptoms are prominent within the same episode of illness. 14.6

Quality Of Life in Schizophrenia The term quality of life was described by Katschnig (1997) as a “loosely related

body of work on psychological well-being, social and emotional functioning, health status, functional performance, life satisfaction, social support, and standard of living, whereby normative, objective and subjective indicators of physical, social and emotional functioning are all used” Schizophrenic patients, over the course of illness, experience increases in their subjective dissatisfaction in the overall quality of life and general health domain, and the psychological domain (Makanjuola et al, 2005). This is in keeping with the “mediational role” hypothesis, which is a quality of life construct theory proposed by Zissi et al (1998). It proposes that in severe mental illness, an appraisal process exists between a patient’s external life condition and other subjective evaluation, and that in making the subjective evaluation, the appraisal process is influenced by cognitive mechanisms such as expectations, aspirations and comparison standards. Similar findings had been reported by Ritsner et al (2000).They observed that respondents who experienced stress, feeling of

23

low esteem and self efficacy had worse subjective quality of life than other respondents who had no similar feeling. Furthermore, a host of studies reported that schizophrenic patients rate their quality of life lower in comparison with the general population (Bobes and Gonzalez, 1997; Skantze et al, 1992) In Nigeria, Gureje and Bamidele (1999) assessed the social, occupational and residential outcomes of schizophrenic patients after thirteen years. A substantial proportion of patients showed a moderate to severe degree of disability in the area of occupation and social contact. Men were particularly disadvantaged in establishing a marital relationship whereas women had a more impaired outcome in the domain of frequency and quality of social contacts. A majority of these patients came from the low social (and occupational) groups but still manifested downward drift on the social ladder. The researchers concluded that the medium to long term traditional family networks may be inadequate to prevent patients with schizophrenia in developing societies from acquiring significant and multiple disablements. Sokoya (1999) assessed the quality of life (using the WHO QOL instruments) of patients consecutively admitted to an in-patient psychiatric unit ward in South western Nigeria. The result revealed that most patients were satisfied with their QOL and socio demographic variables like age, occupational states were significantly associated with QOL of the patients. Adeponle (2003) studied the QOL of 135 patients (100 patients with schizophrenia and 35 with affective disorders) and observed that persons with major mental illness have a good objective QOL and good social outcome in all life areas

24

except for the social relationships domain (Marital status and occupational status). They experienced increased subjective dissatisfaction on the entire QOL domains over the course of the illness. Sex and occupational status were found to correlate with the subjective QOL domain of physical health and psychological health respectively. Olusina and Ohaeri (2003) examined the perceptions of recently recovered psychiatric patients on their feelings of well being, their satisfaction with the domain of living experience and the correlates of subjective quality of life. They found that items of highest satisfaction included overall sense of well being and satisfaction with self. Satisfaction with personal relationships and ability to work were moderate. There was dissatisfaction with adequacy of money to meet needs, dependence on treatment and sex life. At least two-thirds of the subjects were categorized as having average QOL in each of the six domains of living experience. They observed no significant association between psychiatric diagnoses, socio-demographic characteristics and QOL. The authors concluded that the subjective QOL ratings, realistically reflect the strengths and weaknesses of socio-cultural circumstances and patients perceived personal qualities Makanjuola et al (2005) studied a hundred subjects with schizophrenia and found that they had an appreciably good objective QOL and social outcome in all areas of life except for the social relations domain. However, they had experienced increased subjective dissatisfaction in all QOL domains over the course of their illness. A poor correlation was found between respondents’ objective life circumstances and subjective satisfaction. This study showed a significant association between the male gender and performance on overall QOL and general health. Marital status was significantly associated with performance on domain III (Level of independence) on one hand and also

25

between domain III and occupational status on the other hand. Married people and those who were employed tended to have a better score. They implied that marriage and employment are predictors of good QOL in the mentally ill. Of recent, Adewuya (2007) studied 99 patients with Schizophrenia and concluded that despite the problems encountered by the patients and other poor conditions of living, their level of satisfaction with the items of subjective QOL was generally high with self, overall QOL enjoyment, meaningfulness of life and overall health. The least satisfying items were availability of money for everyday needs, sexual life, need for medical treatment, transport and leisure facilities. There was a low to moderate correlation between the patients reported living situations and their satisfaction with their life. 14.7

Factors Affecting Quality Of Life The relationship between the quality of life of patients with schizophrenia and

clinical, socio-demographic, environmental and treatment factors have been explored in many cross-sectional studies. Summary of these studies of general as well as clinical populations have been published (Pinikahana et al, 2002; Sota & Heinrichs, 2004). The relationship between subjective QOL and socio demographic and clinical factors remains controversial. Meltzer et al (1990) reported that negative symptoms may be more important than positive symptoms in determining the quality of life of treatment resistant schizophrenic patients. In addition, quality of life was found to be inversely related to the number of previous hospitalizations, but unrelated to the patients’ age, age of onset of schizophrenia, duration of illness or gender.

26

In contrast, Shtasel et al (1992) found that female subjects had a better quality of life than men. Furthermore, they reported that although female subjects did not differ from males in terms of occupational functioning, they were less impaired with regard to social role functioning and their sense of life involvement. Skantze et al (1992) reported that quality of life was independent of gender, marital status and standard of living but employed patients were found to have a better quality of life. In Nigeria, while Sokoya (1999) and Adeponle (2003) found an association between socio demographic variables and subjective QOL, Olusina and Ohaeri (2003) found no significant association between subjective QOL and sociodemographic variables. The adverse influences of extrapyramidal side-effects on subjective QOL have been documented by several authors (Browne et al, 1996; Awad et al, 2003; Risner et al, 2002). However, others did not find such an association (Gerlach and Larsen, 1999; Reine et al, 2003). Several authors have reported a negative correlation between depression and subjective QOL (Reine et al, 2003; Gorna et al, 2007). Regarding the type of medication used, some studies have suggested that patients on atypical antipsychotics have better subjective QOL than those on conventional antipsychotics (Franz et al, 1997; Awad & Voruganti, 1999; Voruganti et al, 2002; Cook et al, 2002). Some other studies found no difference in the quality of life of patients on atypical antipsychotics compared with patients on conventional antipsychotics (Awad et al, 1997; Hamilton et al, 1999; Stallard & Joyce, 2001; Ritsner et al, 2000). The

role of insight in subjective QOL is controversial. While some studies have

noted a significant association between insight into illness and subjective QOL (Hofer et

27

al, 2004), others studies have found no association (Browne et al, 1998; Doyle et al, 1999; Holloway and Carson, 1999). 15.

Relevance of the Proposed Project to the Practice of Psychiatry Schizophrenia is a worldwide public health problem and a serious concern for

mental health professionals. A number of systematic studies of persons suffering from schizophrenia have observed that there is often a significant co-occurrence of depression in schizophrenia (Siris, 1995). The occurrence of depression in schizophrenia has often been associated with worse outcome, impaired functioning, personal suffering, higher rates of relapse or rehospitalization and even suicide – a tragic event that terminates the lives of an estimated 10% of patients with schizophrenia (Caldwell and Gottesman, 1990; Fenton et al, 1997). The proposed research is relevant to the field of psychiatry in that the knowledge derived from this study will help in defining the relationship between depression and subjective quality of life among schizophrenic patients in our environment. This will assist in the formulation of treatment plans that are aimed at minimising the impact of the disorder and improving the clinical outcome.

28

16. APPLICATION SUPPORTED BY (a)

Head of Department: Name: …………………………………………………… If a Fellow, year of fellowship: ………………………………………………… Signature and Date: ……………………………………………..

(b)

Supervisor: Name: …………………………………………………………… If a Fellow, year of fellowship: ……………………………………………. Signature and Date: ……………………………………………..

(c)

Second Supervisor: Name: …………………………………………………… If a Fellow, year of fellowship: ……………………………………………. Signature and Date: ……………………………………………..

29

17.

FOR OFFICIAL USE ONLY a)

Date of Receipt of proposal ……………………………………

b) Date Forwarded to Chief Examiner or designated assessor ………………. c) Date returned by Chief Examiner or designated assessor ………………….. d) Approved by Chief Examiner (Yes/ No) ……………… e) If not approved, objections must be communicated to the candidate. Date approval/objections communicated. ……………………………………

30

18.

REFERENCES

Addington DE and Addington JM (1992) Attempted suicide and depression in Schizophrenia. Acta psychiatrica Scandinavica 85 (4): 288-291 Addington D, Addington J, Patten S (1996). Gender and affect in schizophrenia. Can J. psychiatry 41:265-268. Adewuya AO (2007) Subjective quality of life of Nigerian Outpatients with Schizophrenia Dissertation submitted to the National Postgraduate Medical College of Nigeria. Adewuya AO, Afolabi MO, Ola BO, Ogundele OA, et al. (2008). Relationshis between depression and quality of life in persons with HIV infection in Nigeria. The International Journal of Psychiatry and Medicine 38 (1): 43- 51 Adeponle AB (2003) A survey of the Quality of Life (QOL) of patients with major mental illness. Dissertation submitted to the National Postgraduate Medical College of Nigeria. Aki H, Tomotake M, Kaneda Y et al (2008) Subjective and Objective quality of life, levels of life skills and their clinical determinants in outpatients with schizophrenia. Psychiatry res. 158:19-25. Andreasen NC, Olsens (1982). Negative Vs positive Schizophrenia: definition and validation Arch Gen Psychitry 39:789-794. Atkinson M, Zibin S, Chuang H (1996). Characterising quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 154; 99-105 Awad AG, Voruganti L (1999). Quality of life and new antipsychotic in Schizophrenia: Are patients better off? Int J Soc Psychiatr 45:268-275.

31

Awad AG, Voruganti LNP, Heslegrave RJ (1997). A Conceptual model of quality of life in Schizophrenia: description and preliminary clinical validation. Qual life Res. 6:21-26. Bartels SJ, Drake RE (1988). Depressive symptoms in Schizophrenia: Comprehensive differential diagnosis. Compr. Psychiatry 29:467-483. Becker RE (1988). Depression in Schizophrenia Hospital and community psychiatry 39(12): 1269-1275. Bermanzohn PC, Siris SG (1992). Akinesia: a syndrome common to Parkinsonism, retarded depression and negative symptoms. Compr. Psychiatry 33:221-232. Birchwood M, Mason R, Macmillan F, Healy J (1993). Depression, demoralization and control over psychotic illness: a comparison of depressed and non depressed patient with a chronic psychosis. Psychol Med. 23:387-395. Bobes J., Gonzalez MP (1997). Quality of life in Schizophrenia. (In Katschnig H, Freeman H, & Sartorius N(Eds), Quality of life in mental disorders (pp. 165-178). New York. Wiley. Bohmer S, Ravens-Sieberer U. (2005) Das Konzept Lebensqualitat in der gesund heitsbezogenen Forschung. In: Schwarzer R (ed) Enzyklopadie Aer Pscychologie. Band 1: Gesundheits psychologie. Gootingen: Hogrefe 369-386. Browne S, Garavan J, Gervin M, Roe M, Larkin C, O’Callighan E (1998). Quality of life in Schizophrenia: Insight and subjective response to neuroleptics. J Nerv Ment Dis 186:7478. Browne SR, Lane A, Gervin M et al (1996). Quality of life in Schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta psychiatr scand. 94: 118-124.

32

Caldwell CB, Gottesman II (1999). Schizophrenics kill themselves too: a review of risk factors for suicide. Schnophr Bull 16:571-589. Carpenter WT Jr, Heinrichs DW, Alphs LD (1985). Treatment of Negative Symptoms. Schizophr. Bull. 11:440-452. Cook PE, Goldberg JO, Van Lieshout RJ (2002). Benefits of Switching from typical to atypical antipsychotic medications: a longitudinal study in a community based setting. Can J. psychiatry 47:870-874. Dalack GW, Healy DJ, Meador-Woodruff JH (1998). Nicotine dependence in Schizophrenia: Clinical phenomena and laboratory findings. Am J. Psychiatry 155:1490-150. DeAlarcon R, Carney MWP (1969). Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br. Med. J. 3:564-567. Doyle M, Flanagan S, Brownes et al (1999). Subjective and external assessments of quality of life in Schizophrenia: relationship to insight. Acta psychiatr Scand 99: 466-472. Drake RF and Cotton PG (1986). Depression, hopelessness and suicide in chronic Schizophrenia. British Journal of psychiatry 148:554-559. Drake, RE, Ehrlich J (1985). Suicide associated with akathisia. Am J psychiatry 142:499-501. Fatoye FO, Adeyemi AB & Oladimeji BY (2004) Emotional distress and its correlates among Nigerian Women in late pregnancy. Journal of Obstetrics and Gynaecology, 24:5:504-509. Fenton WS, McGlashan TH, Victor BJ, Blyler CR (1997). Symptoms, subtype and suicidality in patients with Schizophrenia spectrum disorders. Am J psychiatry 154:1235-1242. First MB, Spitzer RL, Gibbon M et al. (1994). Structured Clinical Interview for the DSM IV AXIS I Disorders, Patient Edition (SCID-P), Version 2, New York State Psychiatric Institute, Biometrics Research, New York.

33

Fitzgerald PB, Williams, CL, Conteling N et al. (2001). Subject and observer – rated quality of life in schizophrenia . Acta psychiatr. Scand 103:387-392. Fleiss JL (1981). Statistical methods for rates and proportions. 2nd Ed. New York: Wiley. Floru L, Heinrich K, Wittek F (1975). The problem of post-psychotic Schizophrenic depression and their pharmacological induction. Int Pharmaco psychiatry 10:230-239. Franz M, Lis S, Pluddermann K et al (1997). Conventional versus a typical narcoleptics: Subjective quality of life in Schizophrenic patients. Br J psychiatry 170:423-425. Galdi J (1983). The causality of depression in Schizophrenia. Br J. psychiatry 142:621-625. Gerlach J, Larsen EB (1999). Subjective experience and mental side effects of antipsychotic treatment. Acta psychiatr Scand. 99: 113-117. Glazer W, Prusoff B, John K, William D (1981). Depression and social adjustment among chronic Schizophrenic outpatients. Journal of Nervous and Mental disease 169 (11): 712-717. Gorna. K., Jaracz K, Wrzyszczynska L, Rybakowski F (2007). Quality of life and depression in schizophrenic patients. Adv. Med Sci. 52 (Suppl 1): 108-111. Griffiths RR, Mumford GK (1995).Caffeine - a drug of abuse? In psychopharmacology: the fourth Generation of Progress. Ed. Bloom FE, Kupfer DJ New York, Raven Press pp 1699 – 1713. Gureje O, Bamidele R (1999). Thirteen-year social outcome among Nigerian out-patients with Schizophrenia. Soc Psychiatry epidemiol. 34:147-151. Hafner H, Maurer K, Treindler G, ander Heiden W, Schmidt M (2005). The early course of schizophrenia and depression. Euro Arch Pscychiatry Cli Neusci. 255:167-173. Halstead SM, Barnes TRE, Speller JC (1994). Akathusia: Prevalence and associated dysphoria in an in-patient population with chronic Schizophrenia. Br J Psychiatry 164:177-183.

34

Hamilton SH, Revicki DA, Edgell ET, et al (1999) Clinical and economic outcomes of olanzapine compared with Haloperidol for Schizophrenia. Results from a randomized clinical trial. Pharmaco-economics 15:469-480. Harper A. & Power M (1998). Development of the World Health Organization WHO QOL – BREF Quality of Life . Psychological Medicine 23:551-558. Harrow M, Yohan CA, Sands JR, Marengo J (1994). Depression in Schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizophr Bull. 20:327-338. Herz MI and Melville C (1980). Relapse in Schizophrenia. American journal of psychiatry 137 (7): 801-805. Hofer A, Kemmler G, Eder U, et al (2004). Quality of life in Schizophrenia: The impact of psychopathology, attitude towards medication, and side effects. J clin. Psychiatry. 65:932939. Holloway F, Carson F (1999). Subjective quality of life, psychopathology, satisfaction with care and insight: an exploratory study. Int J Soc Psychiatry 45:259-267. Hunt SM (1988). The assessment of quality of life in clinical care. Medicographia 10:34-37. Huppert JD, WEISS KA, Lim R et al. (2001). Quality of life in schizophrenia: Contributions of anxiety and depression. Schnophr Res. 51:171-180. Jegede RO (1979). Psychometric Characteristics of Yoruba version of Zung’s self Rating Depression scale and self rating Anxiety Scale. Afr J Med Sci., 8:133-137. Johnson DAW (1981). Depressions in Schizophrenia: Some observations on prevalence, etiology and treatment. Acta psychiatr Scand Suppl 291-137-144. Kaneda Y. (1999) Psychometrics of Zung SDS for schnophrenics. J. Med. Invest 46:75-78. Kasanin J (1933). The acute Schizoaffective psychoses. Am J psychiatry 90:97-126.

35

Katschnig H (1997). How useful is the concept of quality of life in psychiatry? In H. (Katschnig H, Freeman, & N. Sartorius (Eds.), Quality of life in mental disorders (pp 3-15). New York: Wiley. Kay S R., Fiszbeins & Opler LA (1987). The Positive and Negative Syndrome scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13, 262-273. Kholer C, Gur RC, Swanson CL, Petty R, Gur RE (1988). Depression in schnophrenia: I. Association with neuropsychological difiats. Biol psychiatry 43:165-172. Kholer C, Swanson CL, Gur RC, Mozley LH, Gur RF (1998). Depression in schizophrenia: II. MRI and PET Findings. Biol. Psychiatry 43:173-180. Kibel DA, Laffont I, Liddle PF (1993). The composition of the negative syndrome of chronic Schizophrenia. Br. J psychiatry 162:744-750. King DJ, Burke M, Lucas RA (1995). Antipsychotic drug – induced dysphoria. Br J psychiatry 167:480-482. Kirkpatrick B, Fischer B (2006). Subdomains within the negative symptoms of Schizophrenia. Schizophr. Bull 32:246-249. Knights A, Hirsch SR (1981). “Revealed” depression and drug treatment for Schizophrenia. Arch Gen Psychiatry 38:806-811. Krakowski M, Czobor P, Volavka J (1997). Effects of neuroleptic treatment on depressive symptoms in acute Schizophrenic episodes. Psychiatry Res 71:19-26. Kuck J, Zisook S, Moranville JT, Heaton RK, Raff DL (1992). Negative symptomatology in Schizophrenic outpatients. J. Nerv. Ment. Dis. 180:510-515. Lauer G (1997). Zur Lebensqualitat Pscychiatrischer Patienten. Report Pscychologie 22: 122-126.

36

Lawal R.A., Suleiman GT, & Onyeze B. (2003). Risperidone in the treatment of chronic Schizophrenia. Nigerian Medical Practitioner, 44:12-18 Lehman A.F (1996). Quality of life issues and assessment among persons with schnizophrenia. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of Mental health economics and health policy, Vol 1 Chichester, UK: John Wiley & Sons,. Liddle PF, Barnes TRE, Curson DA, Patel M (1993). Depression and the experience of psychological deficits in Schizophrenia. Acta Psychaitr Scand 88:243-247. Lindenmayer JP, Grochowski S, Kay SR (1991) Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms, Compr. Psychiatry 32:528-533. Lysaker PH, Bell MD, Bioty SM, Zito WS (1995) The frequency of associations between positive and negative symptoms and dysphoria in Schizophrenia. Compr. Psychiatry 36:113-117. Makanjuola AB, Adeponle AB, Obembe AO (2005). Quality of life in patients with Schizophrenia in Nigeria. Nigerian Medical Practitioner 2:36-42. McCreadie RG & Ohaeri JU (1994). Movement Disorder in Never and Minimally Treated Nigerian Schizophrenic patients. British Journal of Psychiatry, 164, 184-189. Mcglashan TH, Carpenter WJ Jr (1976). Postpsychotic depression in Schizophrenia. Arch Gen Psychiatry 33: 231-239. Meltzer HY, Burnett S, Bastani R, Ramirez LF (1990). Effects of six months of clozapine treatment on the quality of life of chronic Schizophrenic patients. Hosp Comm. Psych 41:892-897. Mosaku S, Kolawole B, Mume C & Ikem R. (2008) Psychological symptoms and quality of life among diabetic patients: a comparative study. Endocrine Abstracts, 16:244

37

Mulholland C, Cooper S (2000). The symptom of depression in Schizophrenia and

its

management. Adv Psychiatric treatment 6:169-177. Murali T, Kumar Ravi S (2008). Symptoms of depression in schnophrenia. Indian J Med. Res 127: 516-518. Olusina AK, Ohaeri JU (2003). Subjective quality of life of recently discharged Nigerian Psychiatric patients. Soc. Psychiatry Epidemiol. 38:707-714. Pinikahana J, Happell B, Hope J et al (2002) Quality of life in Schizophrenia: A review of literature from 1995-2000. Int J Ment Health Nursing 11:103-111. Pukrop R. (2003) Subjective Lebensqualitat. Kritische Betrachtung eines modernen Konstruckts. Nervenarzt 74: 48-54. Reine G, Lancon C., Di Tucci S et al (2003). Depression and subjective quality of life in chronic phase schizophrenia patients. Acta psychiatr. Scand. 108: 297-303. Rifkin A, Quitkin F, Kane JM, Klein DF (1978). Are Prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 35:483-489. Rifkin A, Quitkin F, Klein DF (1975). Akinesia: a poorly recognized drug induced extrapyramidal behavioural disorder. Arch Gen psychiatry 32:672-674. Risner M, Ponizovsky A, Endicott J et al (2002) The impact of side effects of antipsychotic agents on life satisfaction of Schizophrenia patients: a naturalistic study Eur Psychopharmacol 12:31-38. Ritsner M, Modai I, Endicott J (2000). Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J. Clinical psychiatry 61:11. Sands JR, Harrow M (1999). Depression during the longitudinal course of schizophrenia. Schnophr. Bull 25:157-171.

38

Shear K, Frances A, Weiden P (1983). Suicide associated with akathisia and depot fluphenazine treatment. J Clin psychopharmacol 3:233-236. Sheehan DV, Lecrubier Y, Hamett-Sheehan K et al., (1998). The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 59: 22-33. Shtasel PL, Gur RE, Gallarcher F, Heimberg C, Gur R. (1992). Gender differences in the clinical expression of Schizophrenia. Schnophr Res 7:225-231. Siris SG (1991). Diagnosis of secondary depression in Schizophrenia: Implications for DSM – IV. Schnophr Bull 17:75-98. Siris SG (1995). Depression in schizophrenia. In: Shriqui, CL and Nasrallah HA eds. Contemporary issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press. Pp. 155-166. Siris SG (2000). Depression in schizophrenia: Perspective in the Era of “Atypical” antipsychotic Agents. Am J Psychiatry 157: 1379-1389. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988). Post psychotic depression and Negative Symptoms: an investigation of syndromal overlap. Am J psychiatry. 145:1532-1537. Skantze, K, Malm U, Dencker S, May P, Corrigan P (1992). Comparison of quality of life with standard of living in Schizophrenic outpatients. Br J Psychiatry 161:797-801. Smeets, RMW, Dingmans PMA (1993). Composite International Diagnostic Interview (CIDI), Verse 1.1. WHO Amsterdam. Sokoya AK (1999). A descriptive analysis of the Quality of psychiatric care in a Nigerian University Hospital. Dissertation submitted to West African College of Physician.

39

Sota TL, Heinrichs RW (2004). Demographic, clinical and Neurocognitive Predictors of quality of life in Schizophrenic patients receiving conventional neuroleptics. Comp. psychiatry; 45:415-421. Stallard J, Joyce E (2001) The impact of olanzapine on attitude to medication and quality of life in Schizophrenic. Psychiatr Bull 25:378-381. Subotnik KL, Neuchterlein KH, Asarnow RF, Fogelson DL, Goldstein MJ. Talovic SA (1997). Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. AM J Psychiatry 154:1551-1556. The WHOQOL Group (1998): The WHO Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc. Sci Med 46:1569-1585. Tomotake M, Kaneda Y, Iga J et al. (2006). Subjective and objective Measure of quality of life have different predictors of people with schizophrenia. Psychol. Rep. 99:477-487. Vaillant GE (1964). Prospective prediction of Schizophrenic remission. Archives of General psychiatry 11:509-518. Van Putten T (1975). The many faces of akathisia Compr psychiatry 16:43-47. Van Putten T, May PRA (1978). “Akinetic depression” in Schizophrenia. Arch Gen psychiatry 35:1101-1107. Voruganti L, Cortese L, Oyewumi L et al (2002) Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57:201-208. Voruganti L, Heslegrave R, Awad AG et al (1998). Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 28:165-172.

40

Wassink TH, Flaum M, Nopoulos P, Andreasen NC (1999). Prevalene of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 156: 315-316. WHO (1947) the Constitution o the World Health Organization. Geneva: WHO Wing JK, Cooper JE, Sartorious N (1974). Measurement and classification of psychiatric symptoms. London: Cambridge University Press. Wise RA (1982). Neuroleptics and operant behaviour: The anhedonia hypothesis. Behav. Brain Sc. 5:39-87. Yamauchi K, Hirofumi A, Masahito T et al., (2008). Predictors of Subjective and Objective quality of life in outpatients with schizophrenia. Psychiatry and clinical neurosciences 62:404-411. Zissi A, Barry MM, Cochrane RA (1998). A mediational model of QOL for individuals with severe mental health problems. Psychol. Med. 28:1221-1230. Zung WWK (1965). A Self rating depression scale. Arch Gen Psy, 12:63-70.

APPENDIX THE RELATIONSHIP BETWEEN DEPRESSION AND SUBJECTIVE QUALITY OF LIFE IN NIGERIAN OUTPATIENTS WITH SCHIZOPHRENIA QUESTIONNAIRE

DATE: ___________ HOSPITAL No: ______________________

SECTION A – SOCIODEMOGRAPHIC SECTION

1. AGE: (in years) ____________________

41

2. SEX: Male ( ) Female ( ) 3. MARITAL STATUS: Single ( ) Married ( ) Divorced ( ) Separated ( ) Widowed ( ) Others (specify) ______________________________ 4. RELIGION: Christianity ( ) Islam ( ) Traditional religion ( ) Others (specify) _____________ 5. ETHNICITY: Yoruba ( ) Igbo ( ) Hausa ( ) Others ( please state) ___________________ 6. OCCUPATION: 7. HIGHEST EDUCATIONAL LEVEL: None ( ) Primary ( ) Secondary ( ) Post Secondary ( not University) ( ) University ( ) 8. EMPLOYMENT STATUS: Working full time ( ) Working part time ( ) Unemployed ( ) Retired ( ) In School ( ) Keeping house ( ) Others (specify) ______________________ 9. INCOME/EARNING PER MONTH (in Naira) _______________________________ 10. COST OF TREATMEANT PER MONTH: ( in Naira) -DRUGS: _______________________________________ -TRANSPORTATION: ______________________________ -CONSULTATION: _______________________________________

11. DOMESTIC SITUATION OF PATIENT a) Living in own flat/room b) Living with relatives / friends c) Living in hostel d) Others (specify) ________________________ 12. HOUSING CONDITION/ FACILITIES a) Electricity: Present / Absent b) Pipe borne water: Present / Absent c) Toilet facilities: Present / Absent d) Telephone: Present / Absent 13. MODE OF TRANSPORT TO HOSPITAL a) Public transport b) Own a car c) Own a motorcycle d) Own a bicycle e) Walking 14. LEISURE ACTIVITY (a) Radio/ Television (b) Indoor games (c) Outdoor games 15. RELATIONSHIP WITH SAME GENDER (b) Easy (b) Difficult (c) None 16. RELATIONSHIP WITH OPPOSITE GENDER (c) Easy (b) Difficult (c) None 17. WHAT LEVEL OF SOCIAL SUPPORT DO YOU GET FROM : (a) Family members............ ( Good, Fair ,Poor , None ) (b) Friends.................... ( Good, Fair ,Poor , None ) (c) Government............................ ( Good, Fair ,Poor , None ) (d) Non-governmental organization ( Good, Fair ,Poor , None ) (e) Others (specify).......... ( Good, Fair ,Poor , None ) SECTION B – ILLNESS RELATED DETAILS (1) Duration of illness (in years)___________________________ (2). Age at onset of illness (in years) ________________ (3). Number of episodes of illness ____________________ (4). Number of hospital admissions due to illness_______________________

42

(5) Is the patient currently mentally ill (symptomatic?)____Duration of symptoms ______________ (6). If presently mentally stable, when was the last episode of mental illness (in months) _____ (7). Concomitant medical/physical illness/problems___________________ (8) Global Assessment of Functioning (GAF SCORE) ____________________ SECTION C: MEDICATION RELATED DETAILS Type and dose of antipsychotics (mg/day) 1.) 2.) 3.) 4.) 5.) Other relevant drugs and doses (mg/day) (e.g. Anticholinergic, Antidepressant etc.) 1.) 2.) 3.) 4.) 5.) SIDE EFFECT CHECKLIST – within the last 2 weeks No 1 2 3 4 5

Side effects Present Absent Akathisia Dystonia Parkinsonism Tardive dyskinesia Menstrual dysfunction 6 Sexual dysfunction 7 Dizziness 8 Postural hypotension 9 Reflex tachycardia 10 Sedation 11. Seizures 12 Excessive salivation 13 Blood dyscrasia NMS = Neuroleptic malignant syndrome

No 14 15 16 17 18

Side effects Dry mouth Constipation Urinary hesitancy Blurred vision Photosensitivity

19 20 21 22 23 24 25

Weight gain NMS Skin discoloration Galactorrhea Gynaecomastia Rashes Fever

present

Absent

SECTION D: INSIGHT INTO ILLNESS. (PSE – SECTION 17. BOX 104) 0 = Full insight (in intelligent subject, able to appreciate the issues involved). 1 = As much insight into the nature of the condition as social background and intelligence allow.

43

2 = Agrees to a nervous condition but examiner feels that subject does not really accept the explanation in terms of a nervous illness (e.g. gives delusional explanation, the result of persecution, or rays, etc.) 3 = Denies nervous condition entirely. Rating :

(0- full insight, 1&2= partial insight, 3=Nil insight)

SECTION E: MINI SECTION F: 1) PANSS 2) ZUNGS’ SELF RATING DEPRESSION SCALE SECTION G: WHOQOL

44